Next Article in Journal
Establishment of Efficient Genetic Transformation Systems and Application of CRISPR/Cas9 Genome Editing Technology in Lilium pumilum DC. Fisch. and Lilium longiflorum White Heaven
Next Article in Special Issue
Molecular Inverse Comorbidity between Alzheimer’s Disease and Lung Cancer: New Insights from Matrix Factorization
Previous Article in Journal
Curcumin-Loaded Mesoporous Silica Nanoparticles Markedly Enhanced Cytotoxicity in Hepatocellular Carcinoma Cells
Previous Article in Special Issue
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
Open AccessArticle

Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients

1
School of Medicine, Institute of Medical Sciences, Örebro University, SE-70182 Örebro, Sweden
2
Centre for Systems Biology, Soochow University, Suzhou 215006, China
3
Department of Oncology and Clinical and Experimental Medicine, Linköping University, SE-58183 Linköping, Sweden
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(12), 2919; https://doi.org/10.3390/ijms20122919
Received: 9 May 2019 / Revised: 6 June 2019 / Accepted: 12 June 2019 / Published: 14 June 2019
(This article belongs to the Special Issue Data Analysis and Integration in Cancer Research)
Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer. View Full-Text
Keywords: CHGA; colon cancer; biomarker; early diagnosis; logistic regression; meta-analysis; PPI CHGA; colon cancer; biomarker; early diagnosis; logistic regression; meta-analysis; PPI
Show Figures

Figure 1

MDPI and ACS Style

Zhang, X.; Zhang, H.; Shen, B.; Sun, X.-F. Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients. Int. J. Mol. Sci. 2019, 20, 2919.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop